# A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis

> **NCT07226895** · PHASE1,PHASE2 · RECRUITING · sponsor: **Monument Therapeutics Limited** · enrollment: 150 (estimated)

## Conditions studied

- Clinical High Risk for Psychosis (CHR)

## Interventions

- **DRUG:** MT1988 Low Dose
- **DRUG:** MT1988 High Dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07226895
- **Lead sponsor:** Monument Therapeutics Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-03
- **Primary completion:** 2027-09
- **Final completion:** 2027-10
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-04-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07226895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07226895, "A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07226895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*